MILAN--18 Jun--PRNewswire--AsiaNet/InfoQuest
- Results From Two Large, Multinational, Practice-Based
Observational Studies in Blood Pressure
New data announced today at the Annual European Society of Hypertension (ESH) show that measuring blood pressure in a doctor's office alone does not provide an accurate picture of a patient's blood pressure control. Treatments utilised only on this basis are likely to leave many people at increased risk of heart attack, stroke or even cardiovascular death. According to a further study also presented today, this "unnecessary" additional risk could be avoided by choosing a treatment regimen like once daily telmisartan, which provides smooth blood pressure control over a full 24 hour period, including the risky morning hours.
Results from the SURGE hypertension study, an observational study of blood pressure control outside of a clinical setting, demonstrate that:(1,2)
- More than 60% of patients do not have controlled
Professor Gianfranco Parati, University of Milano-Bicocca, Italy, Chair of the SURGE Steering Committee commented, "The SURGE study is noteworthy because it illustrates that in a real-life setting, despite receiving treatment, a large proportion of patients still have poorly controlled hypertension,particularly in their morning hours. It also highlights the challenges physicians face in getting an accurate picture of blood pressure as HBPM and, even more so, ABPM can not be implemented routinely in every patient in daily
SURGE-2, an 8-week, open-label prospective, practice-based study, assessed the effects of the angiotensin II receptor blocker (ARB) telmisartan in >26,000 patients with hypertension (office blood pressure >140/90mmHg). Blood pressure control was measured using either HBPM (n=25,882) or ABPM (n= 863).
The results(3,4) from this observational study, the largest practise-based study ever conducted in hypertension using this methodology, demonstrate that telmisartan provides powerful blood pressure control over a full 24-hour period, including the risky early morning hours(3,4):
Professor Parati comments, "The results from SURGE-2 are particularly encouraging. They demonstrate that, unlike many other antihypertensive treatments, in telmisartan we have a treatment option that does provide smooth blood pressure control from morning to morning. This is expected to lead to prevention of heart attacks, strokes and even cardiovascular death."
The SURGE studies (SURGE and SURGE-2) are part of an extensive ongoing clinical trial programme, with observational as well as clinical studies investigating the outstanding effects of telmisartan compared with other treatments for hypertension, including other available ARBs. These trials investigate the effects of telmisartan in providing powerful blood pressure reduction from morning to morning, potential organ-protective effects and cardiometabolic protective properties.
Telmisartan has a longer duration of action than all other members of the ARB class; it takes approximately 24 hours for half the dose of telmisartan to be eliminated from the body compared to five to 15 hours for other ARBs(5,6). Clinical trials have already shown that telmisartan provides powerful and consistent blood pressure reduction over a full 24 hour period(5-8).
The results of the SURGE studies in a real life setting further support the hypothesis that, due to its unique pharmacological profile, telmisartan could provide a solution for the ongoing problem of risky blood pressure surges in the morning. Ultimately, telmisartan may give doctors an effective option to protect their hypertensive patients from cardio- and cerebrovascular
Notes to Editors
About organ damage
Complications occurring as a result of uncontrolled hypertension can lead to organ damage.
BRAIN Prolonged uncontrolled hypertension puts the individual at
greater risk of encountering a stroke.
HEART Hypertension increases the workload of the heart. Prolonged
increase of the workload will eventually result in the
enlargement of the heart and increases the risk of heart
failure and heart attack.
KIDNEYS Prolonged hypertension may eventually result in kidney
failure, which in the end-stage may necessitate dialysis
treatment.
EYES Hypertension can damage the blood vessels in the retina and
may result in visual impairment and/or loss of vision.
SURGE studies
SURGE - Survey with HBPM and ABPM Under Real clinical conditions in
An observational study to assess early morning blood pressure control in hypertensive patients
SURGE-2 - Study of a hypertensive population Under treatment with telmisartan in Real clinical conditions with the Goal of controlling Early morning blood pressure rise. A surveillance study of the efficacy of telmisartan (MICARDIS(R)) treatment in reducing early morning blood pressure under real clinical conditions.
About telmisartan (Micardis(R)/Kinzal(R)/Pritor(R))
Telmisartan is a member of the angiotensin II receptor blocker (ARB) class and is being investigated in the most ambitious and far-reaching research programme ever conducted with an ARB. In the ongoing clinical trial programmes ONTARGET, PROTECTION and PRoFESS, over 58,000 patients have been enrolled to investigate the cardiovascular protective effects of telmisartan.
Telmisartan was discovered and developed by Boehringer Ingelheim. Under the trademarks MICARDIS(R) and MICARDISPLUS(R) (combination with HCTZ) the company markets telmisartan in 84 countries around the world, including the USA, Japan and European countries. Telmisartan is marketed in cooperation with Astellas Pharma Inc. in Japan, Bayer HealthCare in Europe and GlaxoSmithKline in selected markets. Bayer HealthCare promotes telmisartan under the brand names Kinzalmono(R), Kinzalkomb(R) (combination with HCTZ), and Pritor(R) and PritorPlus(R) in markets across Europe. Pritor(R) and PritorPlus(R) is also
Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high
In 2006, Boehringer Ingelheim posted net sales of 10.6 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.
For more information please visit www.boehringer-ingelheim.com
Please be advised
This release is from the Corporate Headquarters of Boehringer Ingelheim and is intended for all international markets. This being the case, please be aware that there may be some differences between countries regarding specific medical information including licensed uses. Please take account of this when referring to the material.
References
SOURCE: Boehringer Ingelheim
CONTACT: Ute Schmidt, Corporate Division Communications, Boehringer
Ingelheim GmbH, 55216 Ingelheim/Germany, Phone: +49-6132-77-97296,
Fax: +49-6132-72-6601, E-mail: [email protected]
--Distributed by AsiaNet ( www.asianetnews.net )--
ติดต่อเราได้ที่ facebook.com/newswit